Reports Q3 revenue $331.8M, consensus $288.5M. “The third quarter was a defining moment for Sarepta. We launched ELEVIDYS, our fourth therapy and the first gene therapy for boys with Duchenne muscular dystrophy, we continued to drive great performance of our three PMOs and importantly, on a non-GAAP basis we have achieved profitability, placing us in ever more rarified territory in biotech,” said Doug Ingram, president and CEO, Sarepta Therapeutics. “Reflecting a superb launch, ELEVIDYS net product revenue came in at $69.1 million. Total net product revenue stands at $309.3 million, growing 49 percent over the same quarter last year. And non-GAAP earnings stood at approximately $38.0 million in the quarter, a major milestone for Sarepta.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SRPT:
- Sarepta Therapeutics Inc. Earnings Update: Did it Beat Estimate Forecasts?
- Sarepta call volume above normal and directionally bullish
- Unusually active option classes on open November 1st
- Sarepta price target lowered to $97 from $175 at TD Cowen
- Sarepta Stock (NASDAQ:SRPT) Plunged 37% on Disappointing Elevidys Trial Data